Astrana Health stock hits 52-week low at $22.45

Astrana Health Inc’s stock reached a new 52-week low, hitting $22.45, as the company continues to face challenging market conditions. According to InvestingPro data, despite the stock’s decline, analysts maintain a bullish stance with price targets ranging from $36 to $54, suggesting significant potential upside. Over the past year, Astrana Health’s stock has experienced a significant decline, with a 1-year change of -53.81%. This downturn reflects broader challenges within the healthcare sector and specific hurdles the company is navigating. The new low marks a critical point for investors and analysts, who are closely monitoring Astrana Health’s strategic responses to these ongoing pressures. Despite current market sentiment, the company maintains strong fundamentals with 54.81% revenue growth and positive profitability over the last twelve months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this healthcare provider.

In other recent news, Astrana Health reported its Q1 2025 earnings, which did not meet analyst expectations. The company announced an earnings per share (EPS) of $0.14, falling short of the anticipated $0.30. Revenue also missed projections, coming in at $620.4 million compared to the expected $628.11 million. In addition to financial updates, Astrana Health has made a significant leadership change by appointing Sherry McBride as Chief Operating Officer. McBride brings over 18 years of experience in value-based healthcare operations to the role. Her previous position was COO of Providence Health Network. This appointment is part of Astrana’s strategy to enhance its operational integration and care model during its expansion phase. These developments are crucial for investors to consider as they assess the company’s future trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.